Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against Shigellosis, an infectious gastrointestinal disease caused by...
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against Shigellosis, an infectious gastrointestinal disease caused by Shigella bacteria. The protein is a multiepitope fusion antigen (MEFA), incorporating virulence factors which are conserved across multiple Shigella serotypes.
When administered to animals, this fusion protein induces protection against Shigella epithelial cell invasion. Since virulence factors from multiple serotypes are included in the fusion protein, this protection can be extended to the various Shigella serotypes.
Dr. Paul Hergenrother fhas developed a new series of broad spectrum fusidic acid derivatives. Designed using two distinct methodologies, these fusidic acid derivatives...
Dr. Paul Hergenrother fhas developed a new series of broad spectrum fusidic acid derivatives. Designed using two distinct methodologies, these fusidic acid derivatives feature unique side chains and demonstrate improved MIC values when compared with fusidic acid. One series of derivatives displays antibiotic activity against Gram-negative ESKAPE pathogens, including in clinical isolates of P. aeruginosa. The prodrug displays low toxicity in mammalian cells and human serum experiments suggest that it is less protein bound than Fusidic Acid. A second series of derivatives displays potent activity against clinical isolates of Staphylococcus aureus and Enterococcus faecium and an improved resistance profile in vitro and in vivo when compared to fusidic acid. Additionally, these derivatives display in vivo efficacy against an FA-resistant strain of Staphylococcus aureus in a mouse infection model.
Dr. Pablo Perez-Pinera has developed a method to divide prime editing tools into smaller components that are small enough to be delivered in adeno-associated viruses, an...
Dr. Pablo Perez-Pinera has developed a method to divide prime editing tools into smaller components that are small enough to be delivered in adeno-associated viruses, an FDA-approved vehicle for therapeutic use. Prime editors have recently shown great promise as gene editing tools with greater specificity and fewer off-target effects than existing CRISPR-Cas based methods. This technology has potential as a research tool as well as a therapeutic strategy.
This new class of nanobubbles for the treatment of hypoxia are comprised of FDA approved compounds and provide a biocompatible environment for incorporating pharmaceutical...
This new class of nanobubbles for the treatment of hypoxia are comprised of FDA approved compounds and provide a biocompatible environment for incorporating pharmaceutical agents. Moreover, unlike traditional phospholipid or dextran nanobubbles these new nanobubbles can release their payload without the use of an external trigger such as ultrasound. Additionally, these new nanobubbles have also shown significant promise as a therapy for Central Retinal Artery Occlusion (CRAO).
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against cholera. Cholera is an acute, diarrheal illness caused...
Dr. Zhang from the University of Illinois has developed a promising candidate protein for a vaccine against cholera. Cholera is an acute, diarrheal illness caused by infection of the intestine with the toxigenic bacterium Vibrio cholerae. The protein is a multiepitope fusion antigen (MEFA), incorporating virulence factors which are conserved across multiple Vibrio serotypes.
When administered to animals, the cholera MEFA is broadly immunogenic and induces protective antibodies against Vibrio. Since virulence factors from multiple serotypes are included in the fusion protein, this protection can be extended to the various Vibrio serotypes.
Professor Beth Stadtmueller and Sonya Kumar Bharathkar have created a chimeric secretory immunoglobulin A (cSIgA) with a modified secretory component (SC) that can be used...
Professor Beth Stadtmueller and Sonya Kumar Bharathkar have created a chimeric secretory immunoglobulin A (cSIgA) with a modified secretory component (SC) that can be used in therapeutic treatment. The bispecific cSIgA can bind its target antigen and additional ligands by an engineered SC portion, such as toxins or surface antigens. This can be applied to treatment for mucosal infections such as Clostridium difficile.
